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Introduction
Some patients suffer disabling, frequent migraine with-
out effective treatment as current pharmacological
options are either contra-indicated, poorly tolerated or
overused. A post market pilot programme with the
sTMS device was initiated for patients with migraine.
Aims and objectives
To evaluate patient response to sTMS in an open outpa-
tient setting - To assess the impact of treating migraine
attacks with single pulse sTMS on pain and associated
migraine symptoms over an extended period (minimum
three months) - Understand patient support and educa-
tional needs for using sTMS - Assist patients in estab-
lishing an optimal sTMS treatment scheme for their
migraine patterns - Review options for sTMS within the
UK headache care pathway.
Methods
Clinicians selected patients and prescribed the device.
Patients subsequently received the device to use for a
minimum period of three months. A clinical liaison had
first contact with the patient to discuss treatment and
use. Monthly telephone reviews were conducted to sup-
port and monitor the patients’ treatment and progress.
Survey data was collected monthly over the treatment
period. The patients’ progress with treatment was
reported to their clinician.
Results
Sixty-one patients have been prescribed sTMS from
which 37 (61%) have been using the device for a mini-
mum of three months and completed surveys. A reduc-
tion or alleviation of pain was reported by 73%.
Associated symptoms were improved in 63% of patients
or for some, did not develop. A reduction in the num-
ber of headache days was reported by 53%. When using
the combination of sTMS and a medicine, 30% reported
no headache recurrence. Quality of sleep improved in
17%. The treatment was well tolerated with no adverse
events reported. Conclusion: The sTMS device is a new
and effective acute migraine treatment. This CE marked
device is safe to use in clinical practice and has reliable,
reproducible effects on migraine over time.
Author details
1Princess Margaret Migraine Clinic, London, UK. 2eNeura Therapeutics,
California, USA. 3Royal United Hospital, Bath, UK. 4UCSF, San Francisco, USA.
Published: 21 February 2013
doi:10.1186/1129-2377-14-S1-P222
Cite this article as: Weatherall et al.: Post market pilot programme with
single pulse transcranial magnetic stimulation (sTMS) for
acute treatment of migraine: SpringTMS™™ use in migraine. The Journal
of Headache and Pain 2013 14(Suppl 1):P222.
1Princess Margaret Migraine Clinic, London, UK
Full list of author information is available at the end of the article
Weatherall et al. The Journal of Headache and Pain 2013, 14(Suppl 1):P222
http://www.thejournalofheadacheandpain.com/content/14/S1/P222
© 2013 Weatherall et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
